March 4, 2021 5:46pm

It could be time to crawl over the top and BUY, dollar blazing of some downtrodden and bottoms

Pre-open indication results: 5 HITs and 1 MISS

Numbers based facts speak better then opinion as I see answers in numbers to speak truth over opinion

Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations?  What I provide is a trusted source of share pricing intelligence 

The Dow closed DOWN -345.95 points (-1.11%); the S&P closed DOWN -51.25 points (-1.34%) while the Nasdaq closed DOWN -274,28 points (-2.11)

 

Henry’omics:

Cell and gene therapy sector stocks swung wildly on Thursday following a back-to-back loss.

With today’s steep sell-off, the Nasdaq turned negative on the year with a 1.3% loss.

The volatility came even after a better-than-expected reading on weekly jobless claims.

 

Data docket: First-time filings for unemployment insurance in the week ended Feb. 27 totaled 745,000, a touch below the estimate of 750,000, the Labor Department reported.

 

RegMed Investors’ (RMi) pre-open: “slim pickings. I post about “indication intelligence” devoting my time to collection and analysis of information to identify sector vulnerabilities and strengths.” … https://www.regmedinvestors.com/articles/11796

 

Pre-open indication results:  5 HITs <<SELL: Biostage (BSTG -$0.00 with 2,083 shares “promoted”); Solid Biosciences (SLDB -$1.06), Falling Knife: Applied Genetic Technologies (AGTC -$0.36), Global Blood Therapeutics (GBT -$1.98); Sell into Strength:  MiMedx (MDXG -$1.21) and 1 MISS BUY: Sage Therapeutics (SAGE -$5.52);

 

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

  • Thursday opened negative at 1/32, 1 flat and 1 acquired, stayed negative at the mid-day to 7/26, 1 flat and 1 acquired, closing negative at 3/30, 1 flat and 1 acquired;

 

There are clear winners — and losers — heading into the second month and Q1 of 2021.

Jumping with share pricing momentum:

  • Voyager Therapeutics (VYGR) Mesoblast (MESO), Sangamo Therapeutics (SGMO), to name 3 of the 3 inclining of the 35 covered

Hammered in today’s market:

  • Alnylam Pharmaceuticals (ALNY), Ultragenyx (RARE), ReNeuron (RENE.L), Sage Therapeutics (SAGE), Fate Therapeutics (FATE) to name 5 of the 30 declining of the 35 covered

 

Key metrics:

  • Sector volume was LOW with 0 of the 3-upside having higher than the 3-month average volume with the volume of 19 of 30-downside having higher than the 3-month average volume;
  • Thursday’s percentage (%) of the 3-upside were +0.27% (SGMO) to +0.72% (VYGR) while the 30-downside ranges from -1.90% (KDNY) to -10.73% (MDXG);

 

Thursday’s (3 of 3) incline

  • Voyager therapeutics (VYGR +$0.040;
  • Mesoblast MESO +$0.03);
  • Sangamo therapeutics (SGMO +0.03);

Thursday’s (10 of 30) decliners:

  • Alnylam Pharmaceuticals (ALNY -$6.95 after Wednesday’s -$8.09 and Tuesday’s +$3.94);
  • Ultragenyx (RARE -$6.67 after Wednesday’s +$14.63 and Tuesday’s -$2.54);
  • ReNeuron (RENE.L -$6.50 after Wednesday’s +$4.00, Tuesday’s +$2.50 and Monday’s -$6.00);
  • Sage Therapeutics (SAGE -$5.52 after Wednesday’s -$7.97, Tuesday’s -$3.14 and Monday’s +$2.71);
  • Fate Therapeutics (FATE -$5.35 after Wednesday’s -$7.42);
  • CRISPR Therapeutics (CRSP -$3.59 after Wednesday’s -$10.69);
  • Intellia Therapeutics (NTLA -$3.29 after Wednesday’s -$4.26, Tuesday’s -$2.06 after Monday’s +$3.57);
  • Editas Medicine (EDIT -$2.77 after Wednesday’s -$2.56, Tuesday’s -$1.20 and Monday’s +$3.03);
  • Global Blood therapeutics (GBT -$1.98);
  • uniQure NV (QURE -$1.80);

Closing 1 – Biostage (BSTG) and 1 - Stemline Therapeutics (STML – acquired)

 

Sentiment and COVID-19 infections:

  • Health officials are raising a flag about what appears to be an uptick in coronavirus cases around the world, as virus mutations threaten to disrupt progress in containing the virus.

Infection cases <Million>: never to forget …

  • Thursday 28.76 M cases,
  • Thursday’s death rate totaled 518,482 <Johns Hopkins University>

 

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Thursday, the IBB closed down -2.41% and XBI closed down -3.22%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Thursday was up +1.90 points or +7.12% at 28.57

Upside volume: low

  • Thursday: 0 out of the 3-upside had higher than the 3-month average volume;

Downside volume: low

  • Thursday: 19 out of the 30-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: % and pricing drop

  • Thursday’s percentage (%) of the 3-upside were +0.27% (SGMO) to +0.72% (VYGR) while the 30-downside ranges from -1.90% (KDNY) to -10.73% (MDXG);

 

March, the 3rd month of Q1/21:

Thursday closed negative with 3 advancers, 30 decliners, 1 flat and 1 acquired

 

The BOTTOM LINE: NOT much has changed; scared markets, scare me - I am STILL sending up a red flag on stock pricing until earnings’’ season completes its run.

There is always a shift going-on however, these last two (2) months continues to leave me … QUESTIONING staying longer than a WEEK as I have said recently - my horizon on Monday is to meet on Friday.

As to earnings’ season: “Again, “forewarned … earnings LPS (loss-per-share) season is upon us – my advice, trim and skim … if one can!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.